The role of folic acid in deficiency states and prevention of disease

Journal of Family Practice

Volumn 44, Issue 2, 1997, Pages 138-144

  Swain, Randall A ^a   St Clair, Linda ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

atherosclerosis; Folic acid; homocysteine; neural tube defects; primary prevention

Indexed keywords

FOLIC ACID;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DIET SUPPLEMENTATION; FOLIC ACID BLOOD LEVEL; FOLIC ACID DEFICIENCY; HUMAN; MACROCYTIC ANEMIA; MEGALOBLASTIC ANEMIA; MEGALOCYTOSIS; NEURAL TUBE DEFECT; PRIMARY PREVENTION; REVIEW;

ANEMIA, MACROCYTIC; ARTERIOSCLEROSIS; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; NEURAL TUBE DEFECTS; NUTRITION PHYSIOLOGY; PREGNANCY;

EID: 0031028169     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Zulusky R, Herbert V. Megaloblastic anemia in scurvy with response to 50 micrograms of folic acid daily. N Engl J Med 1961; 265:1033-8.
2. Committee on Dietary Allowances. Recommended dietary allowances. 10th ed. Washington, DC: National Academy Press, 1989.
3. FAO/WHO Expert Group. Requirements of vitamin A, folate and vitamin B12. Geneva, Switzerland: FAO/ WHO, 1987.
4. Alimo K, McDowell MA, Briefel RR, Bischof AM, Caughman CR, et al. Dietary intake of vitamins, minerals, and fiber of persons ages 2 months and over in the United States: Third National Health and Nutrition Examination Survey, Phase 1, 1988-1991. Advance data from Vital and Health Statistics, No. 258. Hyattsville, Md: National Center for Health Statistics, 1994.
5. Herbert V. Nutritional requirements for vitamin B12 and folic acid. Am J Clin Nutr 1968; 21:743-52.
6. Whitney EN, Rolfes SR. Understanding nutrition. 7th ed. St Paul, Minn: West Publishing Company, 1996:361-6.
7. Charley H. Food science. 2nd ed. New York, NY: John Wiley & Sons, 1982:518-20.
8. Ravakhah K, West BC. Case report: subacute combined degeneration of the spinal cord from folate deficiency. Am J Med Sci 1995; 310:214-6.
9. Colman N, Herbert V. Folate metabolism in brain. In: Kumar S, ed. Biochemistry of the brain. Oxford, England: Pergamon Press, 1979:127-42.
10. Colman N, Herbert V. Folates and the nervous system. In: Blakeley RL, ed. Folates and pterins. Vol. 3. New York, NY: John Wiley & Sons, 1986:339-58.
11. Davenport J. Macrocytic anemia. Am Fam Physician 1996; 53:155-62.
12. Breedveld FC, Pieger R, van Wermeskerken RKA. The clinical significance of macrocytosis. Acta Med Scand 1981; 209:319-22.
13. Davidson RJL, Hamilton PJ. High mean red volume: its incidence and significance in routine hematology. J Clin Pathol 1978; 31:493-8.
14. Wymer A, Becker DM. Recognition and evaluation of red blood cell macrocytosis in the primary care setting. J Gen Intern Med 1990; 5:192-7.
15. Morgan SL, Baggott JE, Vaughn WH, Austin JS, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. a double-blind, placebo-controlled trial. Ann Intern Med 1994; 833:41.
16. Herbert V. Biology of disease - megaloblastic anemia. Lab Invest 1985; 52:3-19.
17. Herbert V, Colman N. In: Shils ME, Young VR, eds. Modern nutrition in health and disease. Philadelphia, Pa: Lea & Febiger, 1988:393-410.
18. Das KC, Manusselis C, Herbert V. In vitro DNA synthesis by bone marrow cells and PHA stimulated lymphocytes: suppression by non-radioactive thymidine of the incorporation of 3H deoxyuridine into DNA: enhancement when inadequate vitamin B12 or folate is corrected. Br J Haematol 1980; 44:61-74.
19. Hoffbrand AV. Pernicious anemia Scot Med 1983; 28:228-36.
20. Swain R. An update of vitamin B12 metabolism and deficiency states. J Fam Pract 1995; 41:595-600.
21. Wald N, Sneddon J, Densem J, Frost C, Stone R, MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 1991; 338:131-7.
22. Czeizel AE, Dudas I. Prevention of the first occurrence of neural tube defects by periconceptional vitamin supplementation. N Engl J Med 1992; 327:1832-5.
23. Laurence KM, James N, Miller M, Tennant GB, Campbell H. Double-blind randomized controlled trial of folate treatment before conception to prevent recurrence of neural tube defects. BMJ 1981; 282:1509-11.
24. Smithells RW, Nevin NC, Seller MJ, et al. Further experience of vitamin supplementation for prevention of neural tube defect recurrences. Lancet 1983; 1:1027-31.
25. Kirke PN, Daly LE, Elwood JH. A randomized trial of low dose folic acid to prevent neural tube defects. Arch Dis Child 1992; 67:1442-6.
26. Werler MW, Shapiro S, Mitchell AA. Periconceptional folic acid exposure and risk of occurrent neural tube defects. JAMA 1993; 269:1257-61.
27. Daly LE, Kirke PN, Molloy A, Weir DG, Scott JM. Folate levels and neural tube defects. Implications for prevention. JAMA 1995; 274:1698-1702.
28. Cuskelly GJ, McNulty H, Scott JM. Effect of increasing dietary folate on red-cell folate: implications for prevention of neural tube defects. Lancet 1996; 347:657-9.
29. Scott DE, Pritchard JA. Anemia in pregnancy. Clin Perinatol 1974; 1:491.
30. Rothman D. Folic acid in pregnancy. Am J Obstet Gynecol 1970; 108:149.
31. Smithells RW, Sheppard S, Schorah CJ. Vitamin deficiencies and neural tube defects. Arch Dis Child 1976; 51:944-50.
32. Steegers-Theunissen RP, Boers GH, Trijbels FJ, et al. Maternal hyperhomocysteinemia; a risk factor for neural-tube defects? Metabolism 1994; 43:1475-80.
33. Andersson A, Hultberg B, Brattstrom L, et al. Decreased serum homocysteine in pregnancy. Eur J Clin Chem Clin Biochem 1992; 30:377-9.
34. Mudd SH, Levy HL, Skovby F. Disorders of transulfuration. In: Scriver CS, Beaudet AL, Sly WL, Valle D, eds. The metabolic basis of inherited disease. 6th ed. New York, NY: McGraw-Hill International Book Co, 1989:693-734.
35. Malinow MR. Hyperhomocysteinemia: a common and easily reversible risk factor for occlusive atherosclerosis. Circulation 1990; 81:2004-6.
36. Malinow MR. Homocysteine and vascular occlusive disease. Nutr Metabol Cardiovasc Dis 1992; 1:166-9.
37. Stampfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. JAMA 1992; 268:877-81.
38. Morrison HI, Schaubel D, Desmeules M, Wigle DT. Serum folate and risk of fatal coronary heart disease. JAMA 1996; 275:1893-96.
39. Selhub J, Jacques PF, Bostom AG, et al. Association between plasma homocysteine concentrations and extra cranial carotid-artery stenosis. N Engl J Med 1995; 332:286-91.
40. Giles WH, Kittner SJ, Anda RF, Croft JB, Casper ML. Serum folate and risk for ischemic stroke. First National Health and Nutrition Examination Survey Epidemiologic Follow-up Study. Stroke 1995; 26:1166-70.
41. Verhoef P, Hennekens CH, Malinow MR, Kok FJ, Willett WC, Stampfer MJ. A prospective study of plasma homocysteine and risk of ischemic stroke . Stroke 1994; 25:1924-30.
42. Alfthan G, Pekkanen J, Juhiainen M, Pitkaniemi J, et al. Relation of serum homocysteine and lipoprotein (a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis. 1994; 106:9-19.
43. Falcon R, Cattaneo M, Panzeri D, et al. High prevalence of hyperhomocysteinemia in patients with juvenile venous thrombosis. Arterioscler Thromb 1994; 14:1080-3.
44. Den Heijer M, Blom HJ, Gerrits WBJ, et al. Is hyperhomocysteinemia a risk factor for recurrent venous thrombosis? Lancet 1995; 345:882-5.
45. Den Heijer M, Koster T, Blom HJ, Bos GMJ, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrmobosis. N Engl J Med 1996; 334:759-62.
46. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274:1049-57.
47. Nygard O, Vollset SE, Refsum H, et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA 1995; 274:1526-33.
48. Dudman NPB, Hicks C, Wang J, et al. Human arterial endothelial cell detachment in vitro. Atherosclerosis 1991; 91:77-83.
49. Wall RT, Harlan JM, Harker LA, et al. Homocysteine-induced endothelial cell injury in vitro. Throm Res 1980; 18:113-21.
50. Blann AD. Endothelial cell damage and homocysteine. Atherosclerosis 1994; 94:89-91.
51. Heinecke JW, Rosen H, Chait A. Iron and copper promote modification of low density lipoprotein by human arterial smooth muscle cells in culture. J Clin Invest 1984; 74:1890-4.
52. Heinecke JW, Rosen H, Suzuki LA, Chait A. The role of sulfurcontaining amino acids in superoxide production and modification of low density lipoproteins by arterial smooth muscle cells. J Biol Chem 1987; 262:98-103.
53. Parthasarthy S. Oxidation of low-density lipoprotein by thiol compounds lead to its recognition by the acetyl LDL receptor. Biochim Biophys Acta 1987; 917:337-50.